Balasubramanian Sivakumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Balasubramanian Sivakumar has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Västberg
Department of Process and Life Science Engineering, Lund University, 221 00 Lund, Sweden; Research Institutes of Sweden, 114 28 Stockholm, Sweden
2 shared publications Marie Wahlgren
2 shared publicationsNatalia Markova
2 shared publicationsUlla Elofsson
2 shared publications- Helen Sjögren
Ferring Pharmaceuticals A/S, Amager Strandvej 405, 2770 Kastrup, Denmark
1 shared publication Jan Schaefer
1 shared publication
Latest Publications
- 27 May 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (5)
Safe Handling and Clinical Administration of Antibody Drug Conjugates: Occupational Safety, Material Compatibility, and the Integration of CSTDs into Workflows
Antibody-drug conjugates (ADCs) represent a rapidly expanding class of therapeutics, combining the specificity of monoclonal antibodies with the potency of cytotoxic payloads. Their increasing clinical adoption introduces complex challenges for safe handling, preparation, and administration that extend beyond traditional hazardous drug and monoclonal antibodies - based therapies protocols. These inherent complexities of ADCs necessitate strict controls during handling and administration. This review outlines the current regulatory frameworks and institutional practices guiding ADC's in-use handling and highlights key limitations within these practice systems. We examine current handling practices, including the regulatory and institutional guidance landscape, engineering controls, aseptic compounding environments, and the use of personal protective equipment (PPE), as well as the integration of closed system transfer devices (CSTDs) into clinical and pharmacy workflows. This paper addresses ADC dosing solution stability and administration material compatibility, highlighting risks such as undesired interaction with IV bag materials, tubing, and other administration components while identifying potential gaps in compatibility information availability and accessibility. In addition, the effectiveness of closed-system transfer devices (CSTDs) and their implementation into the clinical workflow are discussed. Finally, we provide recommendations to address the identified gaps to promote safer, more consistent clinical handling practices. Given the complexity of ADC products, the rise of novel ADC constructs, and their expanding application in targeted therapies and alternative administration routes, continued ADC-specific research and regulatory guidance will be essential to achieve safe and effective clinical implementation.
- 27 May 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (5)
Safe Handling and Clinical Administration of Antibody Drug Conjugates: Occupational Safety, Material Compatibility, and the Integration of CSTDs into Workflows
Antibody-drug conjugates (ADCs) represent a rapidly expanding class of therapeutics, combining the specificity of monoclonal antibodies with the potency of cytotoxic payloads. Their increasing clinical adoption introduces complex challenges for safe handling, preparation, and administration that extend beyond traditional hazardous drug and monoclonal antibodies - based therapies protocols. These inherent complexities of ADCs necessitate strict controls during handling and administration. This review outlines the current regulatory frameworks and institutional practices guiding ADC's in-use handling and highlights key limitations within these practice systems. We examine current handling practices, including the regulatory and institutional guidance landscape, engineering controls, aseptic compounding environments, and the use of personal protective equipment (PPE), as well as the integration of closed system transfer devices (CSTDs) into clinical and pharmacy workflows. This paper addresses ADC dosing solution stability and administration material compatibility, highlighting risks such as undesired interaction with IV bag materials, tubing, and other administration components while identifying potential gaps in compatibility information availability and accessibility. In addition, the effectiveness of closed-system transfer devices (CSTDs) and their implementation into the clinical workflow are discussed. Finally, we provide recommendations to address the identified gaps to promote safer, more consistent clinical handling practices. Given the complexity of ADC products, the rise of novel ADC constructs, and their expanding application in targeted therapies and alternative administration routes, continued ADC-specific research and regulatory guidance will be essential to achieve safe and effective clinical implementation.
- Open Access
- 2 March 2026
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 120
Effect of aggregate seeding on protein stability in solution
- 2 March 2026
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 120
Open AccessEffect of aggregate seeding on protein stability in solution
- Open Access
- 14 February 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (4) , 103700
Particle formation during peristaltic pumping of therapeutic proteins: Hofmeister anions effect
- 14 February 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (4) , 103700
Open AccessParticle formation during peristaltic pumping of therapeutic proteins: Hofmeister anions effect